462 related articles for article (PubMed ID: 29378228)
1. The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells.
Landis CJ; Tran AN; Scott SE; Griguer C; Hjelmeland AB
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):175-188. PubMed ID: 29378228
[TBL] [Abstract][Full Text] [Related]
2. The role of octamer binding transcription factors in glioblastoma multiforme.
Rooj AK; Bronisz A; Godlewski J
Biochim Biophys Acta; 2016 Jun; 1859(6):805-11. PubMed ID: 26968235
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies targeting glioblastoma stem cells.
Carrasco-Garcia E; Sampron N; Aldaz P; Arrizabalaga O; Villanua J; Barrena C; Ruiz I; Arrazola M; Lawrie C; Matheu A
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):216-27. PubMed ID: 23607282
[TBL] [Abstract][Full Text] [Related]
4. Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma.
Biserova K; Jakovlevs A; Uljanovs R; Strumfa I
Cells; 2021 Mar; 10(3):. PubMed ID: 33799798
[TBL] [Abstract][Full Text] [Related]
5. Metabolic heterogeneity and adaptability in brain tumors.
Badr CE; Silver DJ; Siebzehnrubl FA; Deleyrolle LP
Cell Mol Life Sci; 2020 Dec; 77(24):5101-5119. PubMed ID: 32506168
[TBL] [Abstract][Full Text] [Related]
6. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells.
Florio T; Barbieri F
Drug Discov Today; 2012 Oct; 17(19-20):1103-10. PubMed ID: 22704957
[TBL] [Abstract][Full Text] [Related]
7. The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.
Mattei V; Santilli F; Martellucci S; Delle Monache S; Fabrizi J; Colapietro A; Angelucci A; Festuccia C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917954
[TBL] [Abstract][Full Text] [Related]
8. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
9. MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells.
Wang X; Huang Z; Wu Q; Prager BC; Mack SC; Yang K; Kim LJY; Gimple RC; Shi Y; Lai S; Xie Q; Miller TE; Hubert CG; Song A; Dong Z; Zhou W; Fang X; Zhu Z; Mahadev V; Bao S; Rich JN
Cancer Res; 2017 Sep; 77(18):4947-4960. PubMed ID: 28729418
[TBL] [Abstract][Full Text] [Related]
10. Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches.
Shakya S; Gromovsky AD; Hale JS; Knudsen AM; Prager B; Wallace LC; Penalva LOF; Brown HA; Kristensen BW; Rich JN; Lathia JD; Brown JM; Hubert CG
Acta Neuropathol Commun; 2021 May; 9(1):101. PubMed ID: 34059134
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways.
Kahlert UD; Mooney SM; Natsumeda M; Steiger HJ; Maciaczyk J
Int J Cancer; 2017 Jan; 140(1):10-22. PubMed ID: 27389307
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of cancer stem cell and tumorigenesis.
Zhu K; Xie V; Huang S
Adv Cancer Res; 2020; 148():1-26. PubMed ID: 32723561
[TBL] [Abstract][Full Text] [Related]
13. STAT3 as a Therapeutic Target for Glioblastoma.
Liu Y; Li C; Lin J
Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
[TBL] [Abstract][Full Text] [Related]
14. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
[TBL] [Abstract][Full Text] [Related]
15. Energy Metabolism in
van Noorden CJF; Hira VVV; van Dijck AJ; Novak M; Breznik B; Molenaar RJ
Cells; 2021 Mar; 10(3):. PubMed ID: 33810170
[TBL] [Abstract][Full Text] [Related]
16. MiR-200c-based metabolic modulation in glioblastoma cells as a strategy to overcome tumor chemoresistance.
Cardoso AM; Morais CM; Sousa M; Rebelo O; Tão H; Barbosa M; Pedroso de Lima MC; Jurado AS
Hum Mol Genet; 2021 Nov; 30(23):2315-2331. PubMed ID: 34245265
[TBL] [Abstract][Full Text] [Related]
17. Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.
Mettang M; Meyer-Pannwitt V; Karpel-Massler G; Zhou S; Carragher NO; Föhr KJ; Baumann B; Nonnenmacher L; Enzenmüller S; Dahlhaus M; Siegelin MD; Stroh S; Mertens D; Fischer-Posovszky P; Schneider EM; Halatsch ME; Debatin KM; Westhoff MA
Sci Rep; 2018 Apr; 8(1):5527. PubMed ID: 29615749
[TBL] [Abstract][Full Text] [Related]
18. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.
Dirkse A; Golebiewska A; Buder T; Nazarov PV; Muller A; Poovathingal S; Brons NHC; Leite S; Sauvageot N; Sarkisjan D; Seyfrid M; Fritah S; Stieber D; Michelucci A; Hertel F; Herold-Mende C; Azuaje F; Skupin A; Bjerkvig R; Deutsch A; Voss-Böhme A; Niclou SP
Nat Commun; 2019 Apr; 10(1):1787. PubMed ID: 30992437
[TBL] [Abstract][Full Text] [Related]
19. Overcoming therapeutic resistance in glioblastoma: the way forward.
Osuka S; Van Meir EG
J Clin Invest; 2017 Feb; 127(2):415-426. PubMed ID: 28145904
[TBL] [Abstract][Full Text] [Related]
20. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
